Experimental 'Exercise Pill' Shows Promise in Early Human Trials
Enveda's drug candidate ENV-308, designed to mimic exercise's appetite-suppressing effects, is safe and well-tolerated in its first human test.
Biotech company Enveda has announced encouraging results from the first human clinical trial of its experimental drug, ENV-308, which aims to curb appetite and replicate some of the physiological effects of physical activity. The drug is designed to mimic a molecule called lactate phenylalanine, or Lac-Phe, which is naturally produced by the body when lactate from exercise combines with the amino acid phenylalanine.
In its first Phase 1 clinical trial, Enveda administered ENV-308 at various doses to 88 healthy adults. The primary goal of the trial was to assess the drug's safety. Researchers found that participants tolerated the drug across all tested dosages, reporting an "exceptional gastrointestinal safety profile." This is a significant finding, as gastrointestinal issues like nausea and vomiting are common reasons for discontinuing other weight-loss medications, such as GLP-1 agonists.
Lac-Phe signals the brain to reduce the drive to eat, and animal studies have shown it can suppress appetite and reduce obesity. However, Lac-Phe breaks down quickly in the bloodstream, limiting its sustained effects. ENV-308 is formulated as a daily oral tablet intended to prolong these benefits.
Beyond appetite suppression, animal studies suggest ENV-308 may help preserve lean muscle mass during weight loss, a benefit not consistently seen with some existing weight-loss drugs. Additionally, animals maintained weight loss after the drug was stopped, addressing the common issue of weight regain experienced by some individuals after discontinuing GLP-1 medications.
The trial also examined the drug's effect on leptin, a hormone that regulates hunger. High leptin levels are common in individuals with obesity, often accompanied by leptin resistance. Early results from the trial indicate that ENV-308 lowered leptin levels, with the most significant reductions observed in participants who started with the highest levels.
Future trials will focus on whether ENV-308 can impact body weight and composition, as well as further investigate its effects on leptin and other metabolic health markers. Researchers will also explore how ENV-308 interacts with GLP-1 medications, with the possibility that it could be used alongside existing therapies, potentially allowing for less frequent dosing of GLP-1s or mitigating some of their side effects.
Enveda is also exploring potential applications of ENV-308 beyond weight management, investigating its efficacy in treating conditions where exercise is known to be beneficial, such as migraines, inflammatory bowel disease, and polycystic ovary syndrome (PCOS).
Despite the promising early results, ENV-308 is still in the early stages of development. Years of further research and successful clinical trials will be required to determine its long-term efficacy and safety before it can be submitted for regulatory approval by the Food and Drug Administration. Even if approved, experts note that exercise offers a broad range of health benefits, including improvements in mental health, cognitive function, sleep, and immune system support, that cannot be fully replicated by a pill.